[Featured Stock] BioLeaders Rises on News of Completion of COVID-19 Vaccine Efficacy Evaluation
[Asia Economy Reporter Jang Hyowon] BioLeaders is showing strong performance following news that it has completed efficacy evaluation of its COVID-19 vaccine.
As of 10:03 AM on the 4th, BioLeaders is trading at 5,700 KRW, up 5.36% compared to the previous day.
BioLeaders announced that it successfully completed efficacy evaluation research for COVID-19 vaccine development in collaboration with the research team from Seoul National University College of Veterinary Medicine. In this joint study, BioLeaders introduced a dual effective antigen targeting both the existing spike protein (S antigen) and the newly targeted nucleocapsid protein (N antigen).
Hot Picks Today
In the End, Fearing a Strike, Samsung Electronics Removes Wafer Pods... Enters 'Emergency Mode'
- No Bacteria Detected in Arisu After 24 Hours of Repeated Drinking from a Tumbler
- "Available Only in Korea": Pokémon Card Prices Surge 2,532% Due to Rarity, Becoming Investment Assets
- Police Summon Narae Park for Third Investigation over Alleged Medical Law Violations
- Pulling Out His Phone for a '360-Degree Selfie' and Giving a Thumbs Up at the Ceiling... "China Is Fascinating" [US-China Summit]
The head of BioLeaders' New Drug Development Division stated, “The nucleocapsid protein is known to constitute the largest portion of the coronavirus and exhibits very high immunogenicity,” adding, “It maintains immune response for up to 11 years, making it a promising target that can complement the shortcomings of existing vaccines, which have difficulty in providing long-term immunity and responding to variants.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
